Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biologic tapering in inactive oligoarticular or rheumatoid factor-negative polyarticular juvenile idiopathic arthritis
2016-000312-15Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of etanercept, adalimumab, tocilizumab and abatacept in juvenile idiopathic arthritis (JIA) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Persistent clinical remission at Week 72 and Safety. Started Jun 2016; status: completed.
02
Drugs
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2016-000312-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000312-15.